Abatacept still an option for difficult SLE cases

Costimulatory blockade remains a possible treatment for systemic lupus erythematosus (SLE) despite negative clinical trials, according to an Australian expert review of abatacept.

The biologic has demonstrated efficacy in rheumatoid arthritis and psoriatic arthritis, but it has not lived up to “tantalizing” pre-clinical evidence of efficacy in SLE, write Monash Health rheumatologist Alberta Hoi (pictured) and Geoff Littlejohn of Monash University.

It’s the first drug targeting co-stimulation

Latest

Trending